Literature DB >> 29134957

Hunting for the mutant without the MAP(K).

Leon Tejwani1,2,3, Janghoo Lim1,2,3,4.   

Abstract

In a paper recently published in Cell Research, Yu et al. identify two MAPK-related kinases, MAPK11 and HIPK3, as positive regulators of levels of mutant huntingtin protein, a toxic species highly involved in Huntington's disease (HD) pathology. The identification and validation of these kinases as therapeutic targets for knockdown in multiple relevant experimental model systems reveal novel potential approaches for treatment of HD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29134957      PMCID: PMC5717406          DOI: 10.1038/cr.2017.140

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  10 in total

1.  Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.

Authors:  A Yamamoto; J J Lucas; R Hen
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

Review 2.  Huntingtin aggregation and toxicity in Huntington's disease.

Authors:  Gillian Bates
Journal:  Lancet       Date:  2003-05-10       Impact factor: 79.321

3.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

Review 4.  Huntington's disease: a clinical review.

Authors:  P McColgan; S J Tabrizi
Journal:  Eur J Neurol       Date:  2017-09-22       Impact factor: 6.089

5.  Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance.

Authors:  Boxun Lu; Ismael Al-Ramahi; Antonio Valencia; Qiong Wang; Frada Berenshteyn; Haidi Yang; Tatiana Gallego-Flores; Salah Ichcho; Arnaud Lacoste; Marc Hild; Marian Difiglia; Juan Botas; James Palacino
Journal:  Nat Neurosci       Date:  2013-03-24       Impact factor: 24.884

6.  A genomewide RNA interference screen for modifiers of aggregates formation by mutant Huntingtin in Drosophila.

Authors:  Sheng Zhang; Richard Binari; Rui Zhou; Norbert Perrimon
Journal:  Genetics       Date:  2010-01-25       Impact factor: 4.562

7.  Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis.

Authors:  Paula Dietrich; Irudayam Maria Johnson; Shanta Alli; Ioannis Dragatsis
Journal:  PLoS Genet       Date:  2017-07-17       Impact factor: 5.917

8.  A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease.

Authors:  John P Miller; Bridget E Yates; Ismael Al-Ramahi; Ari E Berman; Mario Sanhueza; Eugene Kim; Maria de Haro; Francesco DeGiacomo; Cameron Torcassi; Jennifer Holcomb; Juliette Gafni; Sean D Mooney; Juan Botas; Lisa M Ellerby; Robert E Hughes
Journal:  PLoS Genet       Date:  2012-11-29       Impact factor: 5.917

9.  RNAi screening in Drosophila cells identifies new modifiers of mutant huntingtin aggregation.

Authors:  Joanna Doumanis; Koji Wada; Yoshihiro Kino; Adrian W Moore; Nobuyuki Nukina
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

10.  Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models.

Authors:  Meng Yu; Yuhua Fu; Yijiang Liang; Haikun Song; Yao Yao; Peng Wu; Yuwei Yao; Yuyin Pan; Xue Wen; Lixiang Ma; Saiyin Hexige; Yu Ding; Shouqing Luo; Boxun Lu
Journal:  Cell Res       Date:  2017-10-13       Impact factor: 25.617

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.